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Abstract
Non-coding RNAs are much more common than previously thought. However, for the vast majority of non-coding RNAs,
the cellular function remains enigmatic. The two long non-coding RNA (lncRNA) genes DLEU1 and DLEU2 map to a critical
region at chromosomal band 13q14.3 that is recurrently deleted in solid tumors and hematopoietic malignancies like
chronic lymphocytic leukemia (CLL). While no point mutations have been found in the protein coding candidate genes at
13q14.3, they are deregulated in malignant cells, suggesting an epigenetic tumor suppressor mechanism. We therefore
characterized the epigenetic makeup of 13q14.3 in CLL cells and found histone modifications by chromatin-
immunoprecipitation (ChIP) that are associated with activated transcription and significant DNA-demethylation at the
transcriptional start sites of DLEU1 and DLEU2 using 5 different semi-quantitative and quantitative methods (aPRIMES,
BioCOBRA, MCIp, MassARRAY, and bisulfite sequencing). These epigenetic aberrations were correlated with transcriptional
deregulation of the neighboring candidate tumor suppressor genes, suggesting a coregulation in cis of this gene cluster. We
found that the 13q14.3 genes in addition to their previously known functions regulate NF-kB activity, which we could show
after overexpression, siRNA–mediated knockdown, and dominant-negative mutant genes by using Western blots with
previously undescribed antibodies, by a customized ELISA as well as by reporter assays. In addition, we performed an
unbiased screen of 810 human miRNAs and identified the miR-15/16 family of genes at 13q14.3 as the strongest inducers of
NF-kB activity. In summary, the tumor suppressor mechanism at 13q14.3 is a cluster of genes controlled by two lncRNA
genes that are regulated by DNA-methylation and histone modifications and whose members all regulate NF-kB. Therefore,
the tumor suppressor mechanism in 13q14.3 underlines the role both of epigenetic aberrations and of lncRNA genes in
human tumorigenesis and is an example of colocalization of a functionally related gene cluster.
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Introduction
Non-coding RNAs (ncRNA) are emerging as an important
factor for the aberrant gene expression associated with cancer [1].
NcRNA genes are mostly involved in the regulation of target gene
function [2]. Their mode of action varies from posttranscriptional
regulation (i.e. miRNA genes) [3] to modulation of transcription in
cis or in trans, either via competition or blockage mechanisms [4],
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by acting as chromatin organizers that target chromatin modifying
factors (e.g. HOTAIR, KCNLQT1 and XIST) [5]. NcRNA genes
can even act as enhancers themselves [6]. However, for the vast
majority of ncRNAs, the specific cellular function remains
enigmatic.
Two long ncRNA (lncRNA) genes DLEU1 (Gene ID: 10301)
and DLEU2 (Gene ID: 8847) map to a critical region at
chromosomal band 13q14.3 that is recurrently deleted in
hematopoietic and solid tumors (Figure 1) [7–10]. DLEU2 splicing
variants have been suggested to represent the primary transcripts
(pri-miR) of miR-15a (Gene ID: 406948) and miR-16-1 (Gene ID:
406950) because of their localization and coregulation [11]. MiR-
15/16 are among the most strongly and ubiquitously expressed
miRNA genes in human cells [12] and appear to exert a crucial
role in tumorigenesis [13]. In chronic lymphocytic leukemia
(CLL), more than 50% of cases harbor a deletion of the critical
region at 13q14.3 [7,14]. Loss of 13q14.3 is also the most common
aberration in the CLL precursor monoclonal B-cell lymphocytosis
(MBL) [15]. The tumor suppressor mechanism at 13q14.3 is
multifactorial and is likely to involve other genetic elements than
miR-15a/16-1, since (i) knocking out miR-15a and miR-16-1 in
mice leads to a lymphoproliferative disease [16], but rare cases of
CLL have been described where the deletion at 13q14.3 does not
encompass the miRNA genes [10,17,18]. (ii) Deletion of a larger
region at 13q14.3 including adjacent regions in addition to miR-
15a/16-1 leads to more aggressive disease in mice and humans
that more frequently resembles a CLL phenotype [16,18–20]. (iii)
Familial CLL can be associated with deletion of DLEU7 (Gene ID:
220107) localized more proximal in 13q14.3 than with miR-15a/
miR-16 [21].
It remains unclear how the miRNAs and the other candidate
tumor suppressor genes are functionally inactivated in CLL.
Sequence mutations in the miRNA genes that lead to aberrant
processing from primary transcripts occur only very rarely in CLL
[18,22–24]. In addition, the miRNA genes may be more
commonly affected by a processing defect (Allegra et al.,
manuscript submitted). No point mutations have been found in
the other candidate genes at 13q14.3 [25]. However, in support of
their role as tumor suppressors, the two miRNA genes and the
other candidate tumor suppressor genes in the region are
downregulated in CLL cells compared to non-malignant B-cells
[10,13,26,27].
Thus, epigenetic aberrations play a major role in the
pathomechanism of CLL [28–30] and not only the genes but
also regulatory sequences (e.g. CpG islands) are conserved in the
mouse [31]. Accordingly, we have investigated the epigenetic
features of the critical region at 13q14.3 in detail to dissect the
underlying regulatory network.
Interestingly, two genes in the vicinity of the critical 13q14.3
region are imprinted (RB1, Gene ID: 5925 and HTR2A, Gene ID:
3356) [32,33]. Parental imprinting is a mechanism where
epigenetically regulated lncRNA genes control the expression of
genes in cis. Similar to an imprinting mechanism, we recently
found a complex epigenetic regulatory mechanism that involves
asynchronous replication timing and monoallelic expression in
non-malignant B-cells isolated from healthy donors [34,35]. In
addition, the copy of an epigenetic aberration to the homologous
chromosome could account in CLL for the observed high
incidence of loss of heterozygosity at 13q14.3 without loss of
genetic material or the occurrence of mutations [10,36]. Incom-
plete inactivation by epigenetic markers could also explain the
frequent occurrence of genetic loss of the second copy of 13q14.3
in clonal evolution [34,37]. In summary, these findings together
with the transcriptional deregulation in CLL cells made it very
likely that the function of the tumor suppressor mechanism at
13q14.3 is lost through epigenetic aberrations.
We therefore characterized the epigenetic makeup of 13q14.3 in
a thoroughly selected cohort of CLL patients (n = 143, see Table
S1 for patient characteristics), and found significant DNA-
demethylation of two specific sequences within conserved CpG
islands at the transcriptional start sites (TSS) of DLEU1 and
DLEU2/Alt1 (ENST00000425586). This epigenetic aberration was
correlated with transcriptional deregulation of the neighboring
candidate tumor suppressor genes. Such a coregulation in cis of
several tumor suppressor genes points to a functionally related
gene cluster that is involved in the same cellular pathway. In
support of this view we found that the 13q14.3 candidate tumor
suppressor genes KPNA3 (Gene ID: 3839), RFP2 (Gene ID: 10206)
and C13ORF1 (Gene ID: 57213) are positive regulators of NF-kB
activity. In addition, we performed an unbiased screen of 810
human miRNAs and showed the miR-15/16 family of genes to be
the strongest inducers of NF-kB activity. As one major function of
NF-kB in CLL has been shown to be prevention of apoptosis [38–
40], our findings contrast with the supposed role of the 13q14
genes as tumor suppressor genes. Based on these results it will be
tempting to dissect the exact molecular link between 13q14.3 and
NF-kB in CLL. In summary, the tumor suppressor mechanism at
13q14.3 is orchestrated by two epigenetically controlled lncRNA
genes regulating a cluster of genes that impact on NF-kB.
Results
CLL cells display epigenetic marks at 13q14.3 associated
with relaxed chromatin and transcriptional activation
For a comprehensive characterization of the epigenetic make-up
of the critical region at 13q14.3 in CLL cells, DNA-methylation of
the whole region (from ITM2B Gene ID: 9445 to DLEU7) was
quantified in primary patient and healthy proband samples (Table
S1 for patient and Table S2 for healthy proband characteristics).
In addition, the CpG islands of the candidate genes were analyzed
for changes in histone modifications. Applying five different
techniques for detection and quantification of DNA-methylation
[41–45], we found that two regions displayed significantly different
Author Summary
Recent results suggest that genome regions not coding for
proteins are read and transcribed into RNA. While the
function for the majority of the resulting non-coding RNA
molecules remains unclear, some of them are termed
according to their length (typically 200–2,000 nucleotides)
as long non-coding RNA (lncRNA) genes that play a role in
regulating the activity of target genes. In most instances,
this deregulation involves changes of so-called ‘‘epigenet-
ic’’ marks associated with the DNA that are inherited to the
cellular progeny without changes in the DNA sequence.
Here we describe an example where two lncRNA genes
(DLEU1 and DLEU2) are epigenetically deregulated togeth-
er with a cluster of neighboring protein-coding tumor
suppressor genes in almost all patients suffering from
chronic lymphocytic leukemia. Such a common regulation
suggests that the affected genes are involved in the same
cellular pathway. In line with this notion, the 13q14.3
genes modulate the NF-kB signalling pathway, either
inducing or repressing its activity. An activation of NF-kB
has previously been shown to promote survival of the
leukemic cells, underlining the importance of the 13q14.3
tumor suppressor locus for the pathomechanism of the
disease.
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Figure 1. The critical region at 13q14.3 displays relaxed chromatin at the transcriptional start site (TSS) of the long non-coding RNA
genes DLEU1 and DLEU2 in CLL cells. The critical region on 13q14.3 was analyzed for DNA-methylation (lanes 1–3), distribution of histone
modifications (lanes 4, 5) and gene expression (lanes 6, 7). DNA-hypomethylation was detected in CLL cells at the transcriptional start sites of the
lncRNA genes DLEU1 and DLEU2 variant Alt1. This finding coincides with enrichment of H3K4me2 and depletion of macroH2A, corroborating
relaxation of 13q14.3 in CLL. While expression of the protein coding genes and DLEU2 is decreased in CLL cells, lncRNA genes DLEU1 and DLEU2/Alt1
show upregulation, suggesting a direct regulation by DNA-methylation. Base pair positions on top refer to genome GRCh37 build hg18. The
conserved CpG islands (A–E) are shown in green, less stringent CpG islands shown in light green. Lane 1: Methyl-CpG Immunoprecipitation (MCIp)
allowed semi-quantitative DNA-methylation analysis in non-malignant B-cells sorted from healthy donors (n = 7) and CLL samples (n = 25).
Precipitated DNA was hybridized onto a custom tiling microarray covering the 13q14.3 critical region. Depicted is the median log2 fold enrichment of
CLL samples from which the median of log2 fold enrichment of healthy donor B-cell samples has been subtracted. Lane 2: Restriction digest-based
analysis of DNA-methylation (aPRIMES) was performed in CpG islands C–E at 13q14.3 at 1 kbp resolution. Shown is the median log2 signal intensity of
CLL patients from which the median of non-malignant B cell samples has been subtracted. Lane 3: Hypomethylation at D6 and E6 was validated by
BioCOBRA and MassARRAY/Sequenome analyses (for details see Figure 2). Shown is the difference of the median percentage of methylation in CLL
cells and non-malignant B cells. Lanes 4,5: ChIP was performed for macroH2A (lane 4) and H3K4me2 (lane 5). Precipitated DNA was quantified using
qPCR. Enrichment was normalized to non-specific IgG and two control promoters (CDH12, HK2) that displayed similar enrichment for the two histone
marks in CLL samples (n = 7) and peripheral blood mononuclear cells (PBMC) from healthy probands (n = 5). Enrichment was calculated as median
log2 fold enrichment in precipitate vs. input for CLL samples after subtraction of enrichment from non-malignant B-cells. Lane 6: Gene expression
profiling (GEP) was performed using bead chip arrays (Illumina) in CLL patients (n = 25) and sorted B-cells from healthy donors (n = 9). Plotted is the
difference of log fold changes of CLL samples and non-malignant B cells. Lane 7: QRT-PCR for gene expression analysis of 13q14.3 candidate genes
(for details see Figure 3).
doi:10.1371/journal.pgen.1003373.g001
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DNA-methylation patterns in CLL cells compared to non-
malignant B-cells (Figure 1, lanes 1–3; Figures S1, S2). The
differentially methylated regions are localized within the CpG
islands D and E at the transcriptional start sites of the lncRNA
genes DLEU1 (region ‘‘D6’’) and the DLEU2 variant Alt1,
respectively (region ‘‘E6’’; Figure 1, Figure S1 for validation and
S2A, S2B for detail). In a region of chromosomal band 3q25.33
that shows a genetic makeup similar to 13q14.3, no aberrant
DNA-methylation could be detected (Figure S2C, S2D). Also no
differential DNA-methylation was found in CLL at the retino-
blastoma tumor suppressor gene RB1 at 13q14.3 that has been
implicated in the pathomechanism of the disease [16,18], or the
DLEU7 gene (Figure S2D, S2E) [46]. To corroborate the finding
of a relaxed chromatin conformation in CLL, the CpG islands C,
D and E were analyzed for the presence of histone modifications
that correlate with open chromatin and active transcription
(dimethylation of H3K4, ‘‘H3K4me2’’) [47] or with epigenetic
mechanisms leading to transcriptional inactivation (macroH2A)
[48]. In line with a more relaxed chromatin in CLL cells as
compared to non-malignant cells, H3K4me2 showed significantly
more enrichment, while less chromatin was precipitated that
carried the macroH2A modification (Figure 1, lanes 4 and 5).
Therefore unexpectedly, active chromatin marks were detected in
CLL cells at 13q14.3 instead of repressive epigenetic marks that
are characteristic for tumor suppressor inactivation.
Epigenetic aberrations at 13q14.3 are independent of
clinical and genetic characteristics and affect 95% of all
CLL patients
In order to test whether aberrant DNA-methylation is
independent of prognostic and cytogenetic characteristics and
thus a unifying feature of CLL, we analyzed a larger cohort of
CLL patients (Figure 2, Table S1). DNA-hypomethylation was
independent of 13q14.3 gene dosage and was also not a result of
the advanced age of the patients (Figure 2B and 2C, compare age-
matched controls; characteristics are listed in Table S2; for Mann-
Whitney Rank Sum Test see Table S6). Interestingly, DNA-
methylation was significantly retained in CLL cells with a deletion
of 11q22-q23 covering the ATM (Gene ID: 472) gene, and the
most pronounced loss of DNA-methylation was found in patients
with a deletion of TP53 (Gene ID: 7157; Figure 2B and 2C). It can
be speculated that the DNA-damage repair function of the ATM
kinase could be involved in aberrant DNA-demethylation [49] or
that a defect in 11q could be epistatic to loss of function of 13q14.3
[50], but this needs to be shown in further analyses. Finally, levels
of DNA-methylation were not significantly correlated with
mutation status of the immunglobulin heavy chain variable
segment genes (IGHV), an important prognostic marker in CLL
(Figure S3A) [51], or with overall survival (Figure S3B and S3C),
implying that DNA-hypomethylation is present in CLL patients
from all prognostic subgroups. In order to complement the single
time point analyses of DNA-methylation with assessment of the
dynamic changes over time, we analyzed peripheral blood
mononuclear cell (PBMC) samples collected from patients at
different time points during the course of the disease (Figure S3D).
Intriguingly, 4/10 CLL PBMC samples (P7-P10) displayed more
DNA-hypomethylation at 13q14.3 than would be expected from
the content of CLL cells within the PBMC sample. These findings
suggest that DNA-demethylation at 13q14.3 could be an ongoing
process in CLL and should also be studied as a marker for
imminent disease progression.
In summary, DNA-methylation at 13q14.3 was aberrantly lower
in 58 of 61 patients (95%) compared to non-malignant B-cells
(Figure 2D), proposing that DNA-hypomethylation at 13q14.3
seems to be a universal feature of CLL.
13q14.3 genes are a coregulated gene cluster whose
expression correlates with DNA-methylation in CLL cells
Next we investigated the functional impact of the epigenetic
aberrations in 13q14.3. As reported previously, the protein-coding
and the miRNA candidate tumor suppressor genes (including their
host gene DLEU2; [11]) in the critical region are downregulated in
CLL cells (Figure 3A and 3B) [26]. In contrast, the lncRNA genes
DLEU1 and variant DLEU2/Alt1 that display DNA-hypomethyla-
tion at their 59 ends are significantly upregulated in CLL cells
(Figure 3C). To exclude bias caused by the influence of more
complex interrelations e.g. by deletion of the critical region, we
focused on samples with retention of both copies of 13q14.3. We
found a significant inverse correlation of gene expression of the
lncRNA genes DLEU1 and the DLEU2 variant Alt1 [52] with
DNA-methylation levels in regions D6 and E6 that are localized at
their transcriptional start sites. The Pearson correlation coefficient
for DLEU2/Alt1b with D6 was R = 20.33 (p = 0.022) and for
DLEU1 with E6 the coefficient R = 20.28 (p = 0.044; see
Figure 3E, for correlation coefficients see panels F, G). This
suggests the direct regulation of DLEU1 and DLEU2/Alt1 by
DNA-methylation. In contrast, expression of the protein-coding
genes in the region and the miR-15a/-16-1 host gene DLEU2 were
positively correlated with DNA-methylation levels (Figure 3D;
correlation coefficients F, G), suggesting an indirect regulation by
DNA-demethylation e.g. via the lncRNA genes. Levels of mature
miR-15a and miR-16 showed no significant correlation with DNA-
methylation levels, probably because they are subject to additional
posttranscriptional deregulation (Allegra et al., manuscript sub-
mitted). Differences in DNA-methylation supposedly reflects
differential binding of transcription factors, and we comparatively
analysed the sequences at D6 and E6 for binding motifs of
transcription factors by comparing it to the TRANSFAC database
using PATCH (PatchTM public 1.0, http://www.gene-regulation.
com/cgi-bin/pub/programs/patch/bin/patch.cgi). Intriguingly, a
number of transcription factor binding motifs are present both in
the D6 and E6 sequence, further suggesting that these sequences
might be regulated by similar pathways (Table S3).
DNA-demethylating agent 5-aza-29-deoxycytidine
upregulates 13q14.3 genes in cultured cells
In order to understand how DNA-demethylation of D6 and E6
would impact on transcriptional deregulation of 13q14.3, we first
tested 16 cell lines for presence of DNA-methylation at 13q14.3
(Figure S4A, S4B) and whether DNA-demethylation results in
transcriptional deregulation of 13q14.3 candidate genes. Only
Jurkat cells showed DNA-methylation in both loci and could be
DNA-demethylated both at D6 or E6 (Figure S4A–S4F).
Downregulation of the protein-coding candidate genes detected
in CLL cells could not be reproduced in Jurkat cells in-vitro,
probably because either the cellular system (T-cells) or the
treatment does not faithfully reproduce the complex in-vivo
situation (Figure S4F). Interestingly, the levels of mature miR-
15a and miR-16 also remained unchanged, which is in line with a
recent report where incubation of CLL cells with a inhibitor of
histone deacetylases (HDACi) led to upregulation of miR-15a and
miR-16-1 in only 35% of patient samples [53]. These findings
suggest that the miRNA genes are regulated at the post-
transcriptional level in the majority of CLL patients (Allegra,
manuscript submitted). However, as expected we could show that
both lncRNA genes DLEU1 and DLEU2/Alt1 were upregulated in
Epigenetics at 13q14.3 Impact on NF-kB in Leukemia
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Jurkat cells upon DNA-demethylation in-vitro (Figure S4F),
underlining that their transcriptional activity depends on levels
of DNA-methylation.
DNA-demethylation regulates lncRNA expression in vitro
and correlates with CTCF binding in a subset of CLL
patients
In order to test the functional relevance of the hypomethylated
DNA-sequences, their impact on the expression of luciferase
reporter constructs was quantified. The two sequence elements D6
and E6 completely lost their capacity to activate transcription
when they were in-vitro DNA-methylated (Figure 3H and 3I,
Figure S4G–S4J), which is in line with an upregulation of the
lncRNA genes in CLL cells upon DNA-demethylation. In
addition, inclusion of the non-methylated D6 sequence led to a
transcriptional inhibition of the reporter construct in all three cell
lines analyzed, suggesting that transcriptional inhibitors might
bind to the sequence element (Figure 3H and 3I). In contrast, no
changes in transcription were found when the E6 element was
included (Figure S4G–S4J), suggesting that either no transcription
factors would bind to that sequence or that the reporter system did
not faithfully reproduce the in-vivo situation. Both could be the case if
E6 would represent an element of higher order chromatin e.g. a
boundary element. Such an element could be bound by CTCF
protein (Gene ID: 10664), which insulates active chromatin from
heterochromatic gene deserts [30] reminiscent of the region distal to
DLEU1 that is gene-poor. In addition, CTCF has a central role in
transcriptional control exerted by ncRNA genes in cis, probably by
segregating regulatory elements like enhancers and promoters [54],
and its binding to DNA is sensitive to DNA-methylation [55]. In
addition, CTCF binding sites were predicted to be localized close to
or within D6 and E6 (Figure S4K). We therefore tested CTCF
binding at 13q14.3 using ChIP-qPCR, and in fact CTCF binds to
E6 and D6 in a subset of CLL cells but not in sorted B-cells from
healthy donors (Figure 3J). Therefore, CTCF is a candidate for
modulating transcription at 13q14.3 in cis in a subset of CLL cells.
Figure 2. Hypomethylation at the TSS of the large ncRNAs affects the majority of CLL patients independent of 13q gene dosage
and IGHV mutation status. (A) For validation of DNA-hypomethylation at different CpG islands in 13q14.3 (x-axis; for localization see figure 1),
quantitative measurement with BioCOBRA and MassARRAY (‘‘Rb’’) technology was performed in B-cells of healthy donors (‘‘h’’, n = 15–19, white
diamonds) and PBMCs of CLL patients (‘‘p’’, n = 47–82, black diamonds; ‘‘miR’’ = 308 bp fragment spanning miR-15a; ‘‘Rb’’ = intragenic CpG island). (B,
C) CLL patients with different genomic aberrations show different degree of hypomethylation that is distinct from healthy probands younger
(‘‘young’’) or older (‘‘old’’) than 45 years. DNA-methylation was quantified with BioCOBRA (D6) and MassARRAY (E6). Analyzed were patients with
normal karyotype (‘‘nk’’), deletion of 13q14.3 (‘‘13q’’), deletion of 11q22-q23 (‘‘11q’’), deletion of 17p (‘‘17p’’) or combinations thereof. Statistics were
performed using Wilcoxon rank sum test (*** p,0.001, ** p 0.001 to 0.01, * 0.01 to 0.05 and ns not significant p.0.05). (D) DNA-methylation of D6 or
E6 is aberrant in 58/61 CLL patients. Black diamonds: Patient samples with two copies of the critical region in 13q, grey diamonds: samples with
deletion of one copy of 13q14.3, white diamonds: healthy donor samples. Dashed lines represent lowest levels of methylation of non-malignant B-
cells.
doi:10.1371/journal.pgen.1003373.g002
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13q14.3 lncRNA genes do not bind to chromatin
In order to further delineate the regulatory mechanism of the
lncRNA genes DLEU1 and DLEU2/Alt1, we tested whether they
exert their function by binding to chromatin. As expression levels
of DLEU1 and DLEU2/Alt1 were too low for direct visualization of
the lncRNA transcripts using RNA-FISH, we used RNA-seq of
RNA bound to chromatin [56] that was isolated from murine
embryonic stem cells, HeLa and U2OS cells. However, compared
to the other genes localized in the critical region, no significant
enrichment of DLEU1 or DLEU2 transcripts was found to be
bound to chromatin (Figure S5). It is therefore unlikely that
DLEU1 or DLEU2 exert their function by binding to chromatin,
but rather regulate the neighboring cluster of candidate tumor
suppressor genes by divergent transcription (see Discussion). This
coregulation of the 13q14.3 genes implies that they are also
functionally related, e.g. that the respective gene products are
involved in similar cellular processes. To understand which
common pathway is targeted by the 13q14.3 candidate genes,
we analyzed their gene function.
The epigenetically coregulated 13q14.3 genes form a
functional cluster of interacting genes that modulate NF-
kB signalling
For most of the 13q14.3 candidate genes, the associated
molecular function remains unclear. Examples are miR-15a and
miR-16-1, for which a role in regulation of the cell cycle has been
shown [16,57–59]. Interestingly, for these miRNA genes and for
several additional gene products at 13q14.3, an involvement in the
NF-kB pathway has been postulated: miR-15a and miR-16-1
(inducing NF-kB) [60] and DLEU7 (repressing NF-kB) [61]
Figure 3. Downregulation of 13q14.3 candidate tumor suppressor genes and upregulation of lncRNA genes DLEU1 and DLEU2/Alt1
correlates with DNA-methylation. (A–C) Expression of the protein-coding genes KPNA3, C13ORF1 and RFP2, the miRNA genes miR-15a and miR-
16-1 and the lncRNA transcripts from genes DLEU1, DLEU2 and alternative transcript Alt1 were quantified with qRT-PCR in CLL cells from patients with
retention of both copies of 13q14.3 (‘‘p’’, n = 34; see Table S1) and compared to B-cells from healthy donors (‘‘h’’, n = 20). Mean expression is indicated
by a black horizontal line. ‘‘HKG’’ = housekeeping genes, average of PGK, LMNB1 and PPIA. (D, E) DNA-methylation levels correlate with transcript
levels of genes in 13q14.3: While expression (y-axis) of candidate tumor suppressor genes is directly correlated to DNA-methylation of regions D6 and
E6 (x-axis; left panel), lncRNA genes are anti-correlated (right panel). Pearson correlation coefficients are color-coded, blue = negative,
yellow = positive correlation. (F) Pearson coefficients of correlation of gene expression (rows) and DNA-methylation at D6 and E6 (columns),
colour coded (see legend). DLEU1a = exon1 to exon4; DLEU1b = exon 1 to exon 2; ALT1a/b = exon1, two different amplicons (G) Significance values of
Pearson correlation coefficients (t-distribution), values p,0.05 are coded green. (H) The bidirectional promoter of DLEU1 and DLEU2 and the flanking
CpG island was cloned into pCpGL luciferase vector, either including D6 (orange) or excluding D6 (green). (I) Constructs depicted in (H) were either
methylated in-vitro using SSsI methylase (m, dark bars) or left unmethylated (u, light bars) and subsequently transfected into Mec1, Granta519 and
HeLa cells and luciferase activity quantified. Grey: Luciferase CMV expression vector (V) not containing CpGs was used as negative control, green:
excluding D6 region, orange: including D6 region. Error bars signify standard deviation of 2 independent experiments, each performed in duplicate.
No changes were detected for E6 (Figure S4G–S4J). (J) Binding of the DNA-methylation sensitive chromatin reader CTCF was enriched in CLL samples
both in the D6 and E6 regions compared to non-malignant B-cells. CTCF-bound chromatin was immunoprecipitated and quantitated with qPCR.
Specific binding was shown by quantification of a sequence not bound by CTCF 2 kb upstream of the DM1 insulator (‘‘ctr’’). Statistics were performed
using Wilcoxon rank sum test (*** p,0.001, ** p 0.001 to 0.01, * 0.01 to 0.05 and ns not significant p.0.05).
doi:10.1371/journal.pgen.1003373.g003
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modulate this central signalling pathway. For KPNA3, whose loss
leads to an expansion of hemocytes in Drosophila [62], binding of
the NF-kB DNA-binding subunit p65/RELA (Gene ID: 5970) has
been reported, suggesting a NF-kB inductive role [63]. Because of
this suggestive functional link of the 13q14.3 gene cluster, our
further experiments focused on their involvement on NF-kB
signalling.
MiR-15/miR-16 gene family is the strongest inducer of NF-
kB in the miRNome
First we tested whether miR-15a and miR-16 modulate NF-kB
with an unbiased whole genome miRNA (miRNome) screen and
measured NF-kB activity with a luciferase reporter assay [64]. Of
810 miR-mimics transduced into HEK293 cells, the miR-15a/miR-
16 family (miR-15a, miR-15b, miR-16, miR195, miR424, miR497)
showed the strongest induction of NF-kB of all tested miRNA
families (Figure 4A). Compared to a non-specific control miRNA,
transfection of miR-15a and miR-16 miRmics into HEK293 cells
significantly enhanced the induction of NF-kB by TNFalpha
(Figure 4B). In line with this finding, NF-kB target genes like IL6,
IL8, CXCL1 and TNFalpha were induced in three different cell lines
derived from embryonic kidney and breast cancer, albeit with
different induction patterns (Figure 4C–4E), suggesting that the
modulation of NF-kB by the miR-15/16 miRNA family can occur
in different tissues. Thus, in addition to their previously reported
role in regulation of cell-cycle associated genes [16,58,65], the
miR-15/-16 family of genes is capable of inducing NF-kB. As
activation of NF-kB has been shown in CLL cells to prevent
apoptosis [38–40], an inducive effect of miR-15/-16 of this
pathway is difficult to reconcile with their tumorsuppressive role at
least in the tissue analysed here. Therefore to validate an
involvement of miR-15/-16 in NF-kB signalling we sought to
identify target genes that modulate NF-kB in addition to the
previously reported target genes that are associated with cell cycle
progression.
miR-15/miR-16 family represses genes that modulate NF-
kB activity
The miR-15/miR-16 family of miRNAs has been reported to
target several genes involved in NF-kB signalling: IKKa/CHUK, the
NF-kB activating kinase itself (Gene ID: 1142) [66], TAB3 (Gene
ID:257397), an adaptor protein connecting TRAF6 with the NF-kB
Figure 4. MiR-15/miR-16 family is the strongest inducer of NF-kB. (A) NF-kB induction by miRNA families (see Table S5 for complete list) was
measured using NF-kB luciferase reporter assay. Median z-scores are indicated by black horizontal lines. Each dot represents one miRNA-mimic. (B)
Transfection of miRNA-mimics miR-15a and miR-16 induces NF-kB activity as compared to unspecific control siRNA. Error bars represent standard
deviation of triplicate measurements. (C–E) Upon transfection of miRNA mimic miR-15a and miR-16, expression of NF-kB target genes measured by
qRT-PCR is induced in HEK293FT, MCF7 and MDA-MB-231 cells. (F) 39UTRs of genes involved in the modulation of NF-kB activity and shown to be miR-
15a and/or miR-16 targets were cloned into luciferase reporter plasmids. After co-transfection with miR-mimics into HEK cells, firefly luciferase activity
was measured and normalized to renilla luciferase activity and empty luciferase plasmid as transfection and background control, respectively, and to
no-template control (‘‘NTC’’). Data is depicted on a logarithmic scale to balance lower and higher activity compared to control, error bars show
standard error of the mean of three independent experiments.
doi:10.1371/journal.pgen.1003373.g004
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activating kinase TAK1 [60], and the transcriptional coregulator
NCOR2/SMRT (Gene ID: 9612) [67]. As a control we included
SMAD7 (Gene ID: 4092) that is a predicted target of miR-15a
(TargetScan6.2 algorithm), and a negative modulator of NF-kB
activity [68] but has not been validated as a target so far. In order to
delineate the molecular mode of induction of NF-kB activity by miR-
15a, miR-15b and miR-16, the respective miR-mimics were
cotransfected with luciferase reporter constructs containing 39UTRs
or parts of the 39UTRs of the candidate target genes into HEK293T
cells. While constructs containing 39UTRs of genes previously
reported to be targets of miR-15a and/or miR-16 (CHUK/IKKa,
SMRT and TAB3) showed lower luciferase activity after miRmi-
mics-15a/-16 transfection, luciferase activity from the control
reporter SMAD7 selected using in-silico prediction remained
constant (Figure 4F). Thus we reproduced previously reported
findings on gene targets of the miR-15/miR-16 family that
modulate NF-kB transcription factor activity either directly
(NCOR2/SMRT) or via upstream kinases (IKKa/CHUK) or upstream
adaptor proteins (TAB3). The strong induction of NF-kB by the
miR-15/miR-16 family in our screen however suggests that
additional genes are targeted by these miRNAs that are part of
the NF-kB circuitry.
KPNA3 modulates and RFP2 induces NF-kB in HEK293 and
primary CLL cells
We confirmed that knockdown of KPNA3 located in 13q14.3
and the family member KPNA4 (Gene ID: 3840) located in
3q25.33 (Figure S2D) leads to a loss of inducibility of NF-kB
activity by TNFalpha (Figure 5A). However, double knockdown of
both genes did not lead to a full loss of NF-kB induction. In
addition we analysed whether C13ORF1, RFP2 and its bicistronic
ORF KCNRG (Gene ID: 283518), the protein-coding genes closest
to or included in the minimally deleted region, are also involved in
NF-kB signalling. To this end we knocked down candidate genes
from the minimally deleted region and induced NF-kB with
TNFalpha (Figure 5B). Even though TNFalpha activates NF-kB
via several pathways, knocking down RFP2 and, depending on the
NF-kB recognition sequence used, also KCNRG and C13ORF1 led
to a decrease in the activation of NF-kB (Figure 5B, Figure S6A).
To further validate the role of RFP2 in NF-kB signalling, we
exogenously overexpressed RFP2 in HEK293-T, HEK293,
controlled overexpression of RFP2 with a specific antibody we
raised in guinea pig against recombinant full length RFP2 and
quantified NF-kB activity with a luciferase reporter assay
(Figure 5C; Figure S6B). An induction of NF-kB was also observed
when RFP2 was overexpressed in primary CLL cells (Figure 5D).
As overexpression of recombinant proteins may lead to artificial
activation of NF-kB signalling, we separately overexpressed
recombinant GFP as a negative control using 50 fold more
plasmid than RFP2 expression plasmid and did not observe
activation of NF-kB (Figure S6C), underlining that the effect of
RFP2 is specific.
RFP2 activates NF-kB subunits RelA and p105 via its
ubiquitin ligase activity
These findings raise the question how RFP2 activates NF-kB.
NF-kB activation is only induced 7hrs after transfection of the
RFP2 expression plasmid, which is the same time point when the
exogenous RFP2 protein can first be detected (Figure 5C, Figure
S6B). This suggests a direct effect by overexpression of RFP2 and
excludes transcriptional induction of other factors, which would
require at least an additional 1–2 hrs. The activation of NF-kB by
RFP2 could be blocked by dominant negative (dn) IKK and dnIkB
[69], suggesting that the effect of RFP2 takes place upstream of
these factors (Figure 5E). In addition, loss of the ubiquitin-ligase
activity of RFP2 by mutating C13A [70] completely abrogated the
activation of NF-kB by RFP2 (Figure 5E). In order to identify the
NF-kB component that is targeted by RFP2 activation, all DNA-
binding components of the NF-kB signalling pathway were
knocked down individually. Downregulation of RELA and to
lesser extent of p105 (Gene ID: 4790) reduced the activation of
NF-kB by RFP2 (Figure 5F). Corroborating this finding in a
custom oligonucleotide-coupled ELISA (co-ELISA) [71], RFP2
specifically induced the activity of RELA (Figure 5G).
Activation of NF-kB by RFP2 is modulated by VCP
It has recently been shown that the RFP2 protein interacts with
VCP, ATP2A2/SERCA2 [70] and SQSTM1 [72]. We therefore
asked whether these proteins would be involved in the modulation
of NF-kB activity by RFP2. However, knockdown of ATP2A2 and
SQSTM1 did not result in enhanced activity of NF-kB (Figure 5H;
Figure S6D). In contrast, knockdown of VCP substantially
increased the activation of NF-kB by RFP2 (Figure 5H and
Figure S6D). This finding is intriguing as VCP and SQSTM1 link
RFP2 not only to endoplasmatic reticulum associated protein
degradation (ERAD) and autophagy [70,72], but also to regulation
of TRAF6 [73,74] that is involved in signalling pathways such as
CD40/CD40L and TLR that are central to the pathogenesis of
CLL.
RFP2 overexpression stabilizes C13ORF1 protein
RFP2 is a member of the family of tripartite motif proteins
(TRIM) but lacks the SPRY domain (pfam00622) common to other
TRIM proteins [75]. Intriguingly, the neighboring C13ORF1 gene
has a SPRY domain, suggesting a functional interaction of RFP2
and C13ORF1. While knockdown of C13ORF1 led to a reduction in
NF-kB inducibility (Figure 5B), co-expression of RFP2 and
C13ORF1 did not lead to a synergistic induction of NF-kB activity
(Figure S6D). As RFP2 is an integral membrane protein [70] and
requires disruptive RIPA buffer extraction for analysis, physical
interaction with C13ORF1 could not be shown by pulldown
experiments. However, support for the interaction of RFP2 and
C13ORF1 proteins came from the observation that coexpression of
RFP2 stabilized expression of C13ORF1 (Figure 5I), even though
RFP2 has a destabilizing (auto-)ubiquitin ligase activity [70].
Discussion
The functional gene cluster at 13q14.3 is transcriptionally
deregulated by hypomethylation in malignant cells
Several lines of evidence suggest that the tumor suppressor
function of 13q14.3 distal to RB1 is multigenic [16,20] and is not
inactivated by mutation [25], but rather by transcriptional
deregulation [10,13,26,27]. In line with this notion we found
DNA-demethylation at the 59ends of the lncRNA genes DLEU1
and DLEU2 in more than 95% of CLL patients (Figure 2D,
Figure 6A). Hypomethylation in cancer cells usually coincides with
chromosomal instability, which we cannot exclude for 13q14.3, or
with reexpression of silenced oncogenes. In fact, a genome-wide
DNA-demethylation has been observed for CLL cells [76], but the
functional consequence is unclear. At 13q14.3, DNA-methylation
levels comparable to non-malignant B-cells were observed at all
tested loci except for the elements D6 and E6. DNA-demethyl-
ation of the regions D6 and E6 in CLL cells is directly correlated
with an increase in the expression of DLEU1 and DLEU2 and
inversely correlated with the expression of the neighboring
candidate tumor suppressing protein-coding genes (Figure 6B).
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The expression of antisense transcripts is usually lower and is not
necessarily coupled to expression of the respective sense transcripts
[77], which is what we observed at 13q14.3 for the lncRNA genes
DLEU1 and DLEU2 and the protein-coding genes.
As for the cis-regulatory mode of action of lncRNA genes, a
direct RNA-DNA interaction has been shown to recruit repres-
sors, which leads to changes in chromatin conformation [4,78].
However, this option seems unlikely as for none of the
Figure 5. 13q14.3 candidate genes are a functionally related gene cluster that modulates NF-kB signalling. (A) Knockdown of KPNA3
and KPNA4 (x-axis) resulted in reduced stimulation of NF-kB by TNFa in U2OS cells. NF-kB activity was measured after 24 hrs with a reporter driving
luciferase expression under the control of 5 canonical NF-kB recognition sites. SiRNA directed against EGFP was used as negative control. Standard
deviation of duplicate measurements is shown. (B) KPNA3, KCNRG, RFP2 and C13ORF1 were knocked down in HEK293T cells and activity of NF-kB was
measured. As negative control, siRNA without a physiological target was used (siCONP). Error bars signify SEM of 3 independent experiments. (C)
RFP2 induces NF-kB activity in HEK293T and HEK293 (Figure S6B) cells. HEK293T cells were transiently transfected with CMV RFP2 expression plasmids
or empty vector and NF-kB activity measured after 4, 7, 10, 12 and 24 hrs (bottom panel). The top panel is a representative Western blot of two
experiments, error bars in bottom panel represent standard deviation of triplicate measurements. (D) RFP2 induces NF-kB activity in primary CLL cells
(n = 6 patients; CLL3 is beneath CLL5). Experimental setup as in (C). (E) Induction of NF-kB by RFP2 can be inhibited with dominant-negative IkB kinase
(dnIKK) and dominant-negative IkB (dnIKB). HEK293T cells were transfected with expression vector encoding wt-RFP2 or mutant RFP2 in combination
with dnIKK or dnIkB or empty vector, and activity of NF-kB was measured with a luciferase reporter. Inhibition of NF-kB activity by dnIKK and dnIkB
was controlled by stimulation with TNFa 6 hrs after transfection and quantification of NF-kB activity after 24 hrs. (F) RFP2 induces NF-kB activity via
p65 and p105. p105, RELA (p65), cREL, RELB and p100 were knocked down in HEK293 and HEK293T cells that were transfected with RFP2 expression
plasmid. NF-kB activity was measured with luciferase reporter assay. *p,0.05 with students t-test. (G) RFP2 induces DNA-binding of RELA. HEK293T
cells were transfected with empty vector (‘‘empty’’), expression plasmid containing wildtype RFP2 (‘‘RFP2’’), RFP2 with mutated ubiquitin ligase
activity (‘‘RFP2mut’’) or were stimulated with TNFalpha (‘‘TNFa’’). After 24 hrs, DNA-binding capacity of RELA was quantified by co-ELISA. Error bars
represent standard deviation of 2 independent experiments. (H) Knockdown of VCP but not SQSTM1 modulates activation of NF-KB by RFP2. SQSTM1
and VCP were knocked down and plasmids for overexpression of RFP2 and luciferase reporters detecting NF-kB activity were transfected after 24 hrs
into HEK-293. While only a minor change could be observed after knockdown of SQSTM1, knockdown of VCP led to a substantial increase in the
activation of NF-kB after cotransfection of RFP2. (I) Cotransfection of RFP2 leads to stabilization of C13ORF1 protein. HEK-293 and HEK-293T cells were
transfected with wildtype RFP2 or mutated RFP2 lacking ubiquitin ligase activity alone or in combination with C13ORF1. Protein levels of RFP2 and
C13ORF1 were monitored by Western blot. b-actin served as loading control. Experiment is representative of two independent experiments.
doi:10.1371/journal.pgen.1003373.g005
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transcriptional units at 13q14.3 we found substantial enrichment
in the chromatin-bound RNA fraction.
A second mode of action could be competition by (i) ‘‘divergent
transcription’’ of the ncRNA genes that recruits essential factors
away from the candidate tumor suppressor genes [78], (ii) collision
of transcription complexes initiated from different promotors (e.g.
E6 and the DLEU2 promotor) but transcribing through the same
sequences, or (iii) elongation through transcriptional regulators like
enhancers/repressors that leads to the deposit of specialized
epigenetic marks inhibiting transcription from the opposite strand
[79]. Interestingly, D6 seems to inherently harbor transcriptional
repressive properties. The described mechanisms are only
dependent on the initiation of transcription and can be indepen-
dent of the resulting (antisense) RNA molecule itself. The
dispensable role of the DLEU1 transcript itself is also suggested
by the lack of conservation of the DLEU1 gene sequence and its
multitude of splicing variants [8]. In fact, lncRNAs involved in
regulation in cis are in general poorly conserved, probably because
these mechanisms are mostly topological [80] and thus sequence
independent. A topological regulation is also suggested by the
presence of a homologous region on 3q25.33 (Figure S2D) and the
conservation of the orientation of the genes and CpG islands in
Mus musculus [31]. However, it should be noted that in the mouse
there is no overlap of DLEU2 with RFP2, but the sequence
Figure 6. Model of the tumor suppressor mechanism localized in 13q14.3. (A) Regions in CpG islands D and E that are DNA-methylated in
non-malignant B-cells (left) become demethylated in the vast majority of CLL patients (right). This coincides with relaxed chromatin characterized by
absence of macroH2A and enrichment of H3K4me2 at the promoters of the lncRNA genes DLEU1 and DLEU2/Alt1. (B) DNA-hypomethylation is
correlated with transcriptional upregulation of splicing variants of the two lncRNA genes DLEU1 and DLEU2 and inversely correlated with the protein-
coding genes in 13q14.3. No correlation could be found with levels of mature miR-15a and miR-16, probably because these transcripts are also
deregulated by a posttranscriptional processing defect in CLL cells (Allegra, manuscript submitted). (C) Candidate genes localized in the critical region
in 13q14.3 are functionally related and all modulate NF-kB signalling, albeit with different impact. Nuclear transporter KPNA3 is binding NF-kB
components p65 and p50 and is therefore likely a positive regulator like e.g. RFP2. RFP2 binds to C13ORF1 and induces NF-kB activity via the
canonical pathway components p50 and p65, for which its ubiquitin ligase actvity is required. The miRNA genes miR-15a and miR-16-1 were identified
together with other members of this miR family to be among the strongest activators of NF-kB activity. Previously they have been shown to both
modulate cell cycle regulators and inhibit NF-kB via TAB3/TAK1. DLEU7 has recently also been reported to inhibit NF-kB by binding and inactivating
the TACI/BCMA receptors.
doi:10.1371/journal.pgen.1003373.g006
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similarity of the first exon of RFP2 and exon 11 of DLEU2 is
conserved [9]. This suggests at least for this pair of genes the
possibility of a RNAi-like regulatory mechanism. Finally, tran-
scription in the region could be regulated by a central locus control
region, organizing the intranuclear localization of 13q14.3 e.g. by
binding of chromatin organizing proteins like CTCF. While DNA-
methylation dependent aberrant binding of CTCF could be
observed at D6 and E6 in a patient subset, more advanced
experiments (e.g. 3–6C analyses) are required to assess the
functional impact of changed binding properties of chromatin
organizing factors such as CTCF.
Interestingly, epigenetic deregulation of lncRNA genes leading
to aberrant transcription of neighboring genes occurs also in acute
leukemia. The lncRNA HOTAIRM1 for example is expressed
exclusively in the myeloid lineage and controls expression of the
proximal HOXA gene cluster [81]. Similarly, the ncRNA vault
RNA2-1 (vtRNA2-1) in the commonly deleted region of chromo-
some 5q is monoallelically methylated and expressed in healthy
individuals, while it is epigenetically inactivated in AML, leading
to activation of NF-kB via RNA-binding protein kinase R (PKR,
[82]). Another example resembling the molecular mechanism of
the 13q14.3 locus is silencing of the tumor suppressor WT1 by the
overlapping WT1-antisense lncRNA WT1-AS, which is mono-
allelically expressed in non-malignant cells and becomes activated
in AML by hypomethylation [83]. Thus, epigenetic deregulation
of ncRNA genes seems to be a recurrent disease related
phenomenon both in chronic and acute leukemias, leading to
aberrant function of tumor suppressor- or oncogenes.
The tumor suppressor genes at 13q14.3 are
transcriptionally coregulated and modulate NF-kB
signalling by either activating or repressing the pathway
The transcriptional activities of the 13q14.3 candidate genes all
correlate with the DNA-methylation levels in the region. This co-
regulation suggests that 13q14.3 genes are also functionally
related, i.e. are involved in the same cellular pathways. Such
clusters of genes seem more common in drosophila than in
mammalian cells [84]. In human cells, only a subset of
ubiquitously expressed genes and a small set of atypical genes is
grouped together into coregulated clusters [85]. A reason for
evolutionary conservation of a genetic neighbourhood of func-
tionally connected genes is the coregulation of these genes [85].
Examples in the mammalian system are the globin gene family,
groups of olfactory receptors, histone-coding genes, HOX genes,
genes of the major histocompatibility complex and imprinted
genes. In addition, most long non-coding RNA genes are involved
in regulating functionally related gene clusters [2]. One major
unifying scheme of these gene clusters seems to be the
transcriptional activity from the same chromosomal strand [85],
which has been shown for 13q14.3 [35]. Similarly, the topological
organization of these gene clusters is highly conserved between
mammals, which is also true for 13q14.3 [31,50] and its
homologous cluster at 3q25.33. It is therefore very likely that the
13q14.3 candidate genes are also functionally related, and we and
others could show that they activate or repress the NF-kB
signalling pathway (Figure 6C).
NF-kB signalling is centrally involved in the homeostasis of the
hematopoietic system where it is induced in inflammation and
inhibits apoptosis [86]. NF-kB signalling has already been shown
to be activated in CLL cells [38–40,87], where it is postulated to
help in cellular survival [87]. In CLL, NF-kB is activated by the
interaction with the microenvironment [39], which is crucial for
the survival of CLL cells [51]. NF-kB is also activated via the B-cell
receptor (BCR) that plays an important role in the pathogenesis of
CLL [51]. Similarly, NF-kB is activated by interaction of TCL1
(Gene ID: 8115) and ATM in CLL [88], two genes that are
coregulated in CLL cells [89] and centrally involved in the
pathogenesis of CLL. In contrast, in early developmental stages of
a CLL-like disease in transgenic mice, repressive p50/p50 NF-kB
dimers (Gene ID: 4790) cause epigenetic lesions that even precede
genetic lesions [29], suggesting that at different stages of the
disease, NF-kB could play different roles.
Genome- and exome-wide analyses of CLL cells have recently
shown that mutations are present in genes involved in NF-kB
signalling [90], and intriguingly mutations in a NF-kB-pathway
associated gene (MYD88, Gene ID: 4615) seem to be even
enriched in del(13q) patients [91]. This is most interesting as
MYD88 is required for TLR signalling via TRAF6, a protein that
is bound by SQSTM1 and VCP [73], which interact with RFP2
[70,72]. Further studies will be required to understand the
molecular interplay of these proteins in full detail and especially
to accommodate the unexpected induction of NF-kB activity by
several genes localized at 13q14 with their tumorsuppressive
function.
After recent reports have shown 13q14.3 genes to be inhibitors
of NF-kB signalling [60,61], here we demonstrate that the miR-
15a/16 cluster, KPNA3 (and KPNA4 from 3q25.33) and RFP2 are
positively correlated with NF-kB function (Figure 6C): the
miRNA15/16 family of genes were among the strongest inducers
of NF-kB in an unbiased screen, KPNA3 is the transporter of p65
and RFP2 induces canonical NF-kB signalling. NF-kB activity is
normally associated with an inhibition of apoptosis, and in fact has
been shown to be induced in CLL cells by pro-survival
microenvironmental stimulants like e.g. CD40L, BAFF; stromal
cells or B-cell receptor stimulation [38,87,92–94]. However, there
are a few instances where NF-kB activity can also induce
apoptosis. The most relevant example is probably the negative
selection of T-cells [95], where strong signalling from the T-cell
receptor upon recognition of self-antigens induces apoptosis via
activation of NF-kB above a certain threshold. While in B-cells
negative selection is somewhat dissimilar, loss of negative selection
in CLL cells would make sense considering i) the autoreactivity of
CLL cells and ii) the importance of consistent BCR signalling
induced by self-antigens in the pathogenesis of the disease [96].
Thus, even though within the same cell, NF-kB activity cannot be
at the same time silenced and activated, the activity of NF-kB can
change during the leukemogenesis of CLL and the role of the
tumor suppressor mechanism in 13q14 could be required only at
specific timepoints. The speculative involvement of 13q14 genes in
negative B-cell selection could explain how deletion of NF-kB-
inducing genes at 13q14 would lead to CLL leukemogenesis at an
early timepoint, while malignant B-cells from of terminal stage
CLL then exhibit increased levels of NF-kB that prevent apoptosis
as has been shown previously (see above). In this respect it should
be borne in mind that the functional assays quantifying the impact
of 13q14 genes on NF-kB signalling performed both by us and by
others depend on in-vitro experiments mostly in cell lines and not
in primary cells except for RFP2 (Figure 5D). In addition,
overexpression and knockdown of 13q14 genes was performed
using recombinant constructs. These experimental settings and
their results might therefore not properly reflect the physiological
situation, especially when looking at such finely tuned systems like
NF-kB signalling. However, NF-kB has been shown to be a
promising target for therapeutic intervention in CLL cells [97,98],
and further functional experiments and especially in-vivo analyses
should be performed to fully understand the mechanistic link
between 13q14 and NF-kB in CLL.
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Conclusion and outlook
In summary, we uncovered a cluster of functionally related
genes that are coregulated by long non-coding RNA genes in cis
and are epigenetically deregulated in malignant cells. We
previously speculated that the epigenetic deregulation could
explain a stepwise inactivation of the tumor suppressor mechanism
[34]. This would complement the findings of clonal evolution and/
or extent of 13q14 deletion being associated with a more
aggressive form of CLL [18,37], and the presence of pre-
malignant stages of the disease (e.g. MBL) [15]. Further work is
required to identify transcription factors binding to the demeth-
ylated regions and characterization of their intranuclear localiza-
tion. It will also be of interest to test whether the observed
epigenetic aberrations are present already in premalignant cells of
mouse models [23,99] or whether they constitute the aberrations
that have been postulated to be present in hematopoietic stem cells
of CLL patients [100].
Materials and Methods
Magnetic depletion and isolation of cells
Mononuclear cells were isolated from peripheral blood by density
centrifugation using Ficoll (Biochrom AG) according to the
manufacturer’s instructions. For positive selection of CD19+ B-cells
and CLL cells from peripheral blood, mononuclear cells (PBMCs)
were labeled with CD19 MACS magnetic MicroBeads and isolated
using MACS LS Column placed in the magnetic field of MACS
Separator. The purity of the CD19+ fraction was 95%63% (6
SEM) after purification from PBMCs from healthy probands and
97%62% for purification from PBMCs of CLL patients as
measured by flow cytometry (FACSCalibur, BD Biosciences) using
anti-CD19 FITC-labeled antibodies (anti-CD19 MicroBeads,
Dako) that specifically binds the CD19 epitope.
Ethics statement
Peripheral blood samples were obtained from patients after
informed consent by a procedure approved by the Ethics
Committee of Ulm University (approval 96/08), and peripheral
blood was drawn from fully anonymised age-matched healthy
probands at the german red cross (DRK) in accordance with the
Declaration of Helsinki.
QPCR (quantitative PCR) analysis and reverse
transcription (RT)
Standard 20 ml qPCR reactions contained 10 ml SYBR Green
mixture (Absolute QPCR SYBR Green ROX Mix, Thermo
Scientific) and primers at 70 nM final concentration. Thermal
cycling conditions were 15 minutes at 95uC, 40 cycles of 15 s at
95uC and 30 s at 60uC, dissociation curve 15 s at 95uC, 15 s at
60uC and heated to 95uC (within 20 minutes), held for 15 s and
cooled down to 4uÇ using the 7300 Real-Time PCR system
(Applied Biosystems). A standard curve, using template dilutions of
HeLa and HEK293 cDNA was measured to determine PCR
efficiency and allow exact quantification of template. All primers
used for qPCR are listed in the Table S4. Reverse transcription of
total RNA was carried out using the AffinityScript QPCR cDNA
Synthesis Kit (Agilent), a reaction lacking reverse transcriptase (-
RT) was included for each template where primers did not span an
intron and amplification of product would have been possible from
contaminating genomic DNA. For mRNA detection, Ct-values
were normalized using dilution standard curves and three
housekeeping genes (PGK2, LMNB1, PPIA) or for the miRNA
genes using the ddCT method with RNU6B and SNORA73A as
internal normalization controls.
MiRNA detection
10 ng of total RNA was reverse transcribed using the miScript
Reverse Transcription Kit (QIAGEN) where reactions were scaled
down to 10 ml. The completed RT reactions were diluted to 50 ml
with DEPC-treated water and PCR amplification for real-time
quantitative analysis was performed using the miScript SYBR
Green PCR kit (QIAGEN). Total reaction volume of qPCR was
20 ml, and 2 ml of the diluted RT reactions were used as template.
For miRNAs custom forward primers were used to final 0.5 mM
(sequences see Table S4) and primers for normalization controls
RNU6B and SNORA73A were purchased from QIAGEN. The
annealing temperature was 55uC.
Cloning of 13q14.3 constructs into pCpGL vector
To study the effect of DNA-methylation in vitro, the regions D6
and E6 were cloned with their physiological promoter into the
pCpGL vector (kind gift from Michael Rehli) [101] to investigate
their impact on transcription and whether this is dependent on
DNA-methylation. The promoters of the large ncRNAs DLEU1/
DLEU2 and DLEU2/Alt1 were cloned in both directions with and
without the putative regulatory elements D6 and E6. The
construct containing D6 was 2 kb in size and the construct lacking
D6 was 1.3 kb in size. These products could be amplified from
placenta DNA (SIGMA-Aldrich) using the HotStarTaq Plus PCR
system (Qiagen; cycling: 95uC: 5 min; 40 cycles of 95uC: 30 sec,
58uC: 30 sec, 72uC: 1/1.5 min; hold 10uC). Constructs containing
or not containing E6 were 4000 and 3500 bp in size and amplified
with the Expand High Fidelity PCR System (Roche) using PAC
372-3 from 13q14.3 as template [7]. Cycling was performed 95uC
2 min, 106[95uC 20 s, 60uC 30 s, 68uC 4 min], 206[95uC 20 s,
60uC 20 s, 68uC 4 min +20 s in each cycle], 68uC 7 min, hold
4uC. The desired constructs were amplified with primers
containing BamH1 and SpeI recognition sites (see Table S4) and
cloned into the TOPO TA cloning vector (Invitrogen). Plasmids
from positive clones were digested with BamH1 and SpeI (NEB)
using 3 mg TOPO-plasmid-insert-DNA or 1 mg pCpGL vector for
1 h at 37uC. The insert was isolated on a 1% agerose gel (50 min,
150 V) and extracted using QIAEX II Kit (Qiagen). For sticky end
ligation a 3 times molar excess of insert over pCpGL vector
backbone was used in a ligation reaction with 0.1u T4 ligase
(Invitrogen) incubating 1 h at 37uC or at 16uC over night.
The ligation reaction was purified by ethanol precipitation,
resuspended in 5 ml water and 1 ml was used to transform
competent PIR1 E.coli cells (Invitrogen) bacterial cells via
electroporation (Gene Pulser II, BIO-RAD). After electroporation
in a 2 mm cuvette at 25 mF and 2.5 kV setting the pulser at 2006,
transforming 50 ng DNA within a total volume of 400 ml, cells
were plated on zeocin containing plates and incubated at 37uC
overnight. For transient transfections, plasmids were isolated and
purified using the EndoFree Plasmid Kit (Qiagen). In vitro
methylation was performed using SssI methylase (NEB) according
to manufacturer’s instructions but incubating for 4 h at 37uC and
adding 1 ml fresh SAM after 2 h.
Cloning of 39UTRs of miR target genes into pMIR-Report
plasmid
To measure the impact of miR-15a, miR-15b and miR-16 on
potential target genes, parts of or the whole 39UTRs of TAB3,
CHUK, SMAD7 and SMRT were cloned into the vector pMIR-
Report (Applied Biosystems). Sequences containing the miR target
sites in the 39UTRs of TAB3, CHUK, SMRT ‘‘KF’’ and SMAD7
were amplified from HEK293T genomic DNA using the
corresponding primers (containing restriction sites for HindIII,
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SpeI or SacI; see Table S4) and the PRECISOR high-fidelity
DNA polymerase (BioCat) according to the manufacturers
instructions. Amplified products were purified using the PCR
Purification Kit from Qiagen, digested with HindIII, SpeI or SacI
(FastDigest Enzymes, Fermentas) and ligated with pMIR-Report
(T4 DNA Ligase, Fermentas). Plasmid backbone had been
digested with the respective enzymes and purified via agarose
gel extraction (Qiagen). Reporters containing just the miR target
site and the respective mutated sequence (‘‘SMRT’’ and
‘‘SMRTmut’’) were cloned as described previously [67].
Bisulfite conversion
1 mg of genomic DNA was converted using EpiTect 96 Bisulfite
Kit or EpiTect Bisulfite Kit (Qiagen) in a GeneAmp PCR System
2700 (Applied Biosystems) with a reaction volume of 100 ml. After
desulphonation, converted DNA was eluted 2 times in 20 ml
prewarmed (65uC) water. Bisulfite conversion was performed on
dilution series (different degree of methylation) of placenta DNA
(SIGMA-Aldrich), DNA from CLL patients and from B cells of
healthy individuals for quantitative methylation analysis by
BioCOBRA or massARRAY as well as bisulfite sequencing.
BioCOBRA
For BioCOBRA analysis (combined bisulfite restriction analysis
with the Agilent 2100 Bioanalyzer platform, [102], bisulfite
converted DNA was amplified using primers specific for converted
template (see Table S4). After purification of the PCR products
using Rapid PCR Purification System (Marligen Biosciences),
products were digested with BstUI (NEB) over night at 60uC.
Fragments were subsequently analysed with DNA 1000 LabChip
(Agilent) on the Agilent 2100 Bioanalyzer. For all amplicons a
calibration curve was measured with defined mixtures of
methylated and unmethylated DNA (Figure S1A). Fully unmethy-
lated DNA was generated by whole genome amplification
(REPLI-g Kit, Qiagen), and after purification (QIAamp DNA
Mini Kit, Qiagen), half of the amplified and purified DNA was in
vitro methylated using SssI methylase (NEB).
MassARRAY
Mass-spectrometric methylation analysis was performed using
MassARRAY (Sequenom) analysis according to [42] for the
potential regulatory element E6 within 13q14.3, because lack of a
BstUI recognition site precluded BioCOBRA. The target gene
regions were amplified by PCR (see Table S4) after sodium-
bisulfite conversion of template DNA using primers specific for
converted template. In this amplification, reverse PCR primers
were tagged with the T7 recognition sequence for reverse
transcription. Deoxynucleotides in the PCR reaction were
dephosphorylated using shrimp alkaline phosphatase (SAP) at
37uC for 20 min followed by 5 min heat inactivation of SAP at
85uC. Making use of the T7 recognition sequence, a single-
stranded RNA copy of the template was generated by in vitro
transcription. The produced RNA was cleaved specifically at
Uracil by RNase A. The cleavage products were analyzed using
matrix-assisted laser desorption ionization – time of flight
(MALDI-TOF) mass spectrometry in a final elution volume of
27 ml. Cleavage product signals with a 16 Da shift (or a multiple
thereof) represent methylation events; signal intensity was corre-
lated with the degree of DNA-methylation.
Bisulfite sequencing
Bisulfite converted DNA (EpiTect Bisulfite Kit, Qiagen) was
amplified using primers specific for converted DNA. After PCR
purification (Rapid PCR Purification System, Marligen Bioscienc-
es) the product was cloned into pCR2.1-TOPO vector and
subsequently transformed into One Shot Mach1-T1 competent E.
coli cells (Invitrogen). Positive clones were selected by colony PCR
using M13 primers; cycling: 95uC: 12 min; 40 cycles of 95uC:
30 sec, 55uC: 30 sec, 72uC: 1 min; 72uC: 7 min; hold 10uC. PCR
products of the expected size were purified (Marligen Biosciences)
and sequenced (BigDye Terminator v3.1 Cycle Sequencing Kit,
Applied Biosystems) using M13 forward primer with the ABI
Prism 3100 Genetic Analyzer 3130xl (Applied Biosystems).
Cycling: 96uC: 1 min; 25 cycles of 96uC: 10 sec, 52uC: 5 sec,
60uC: 2 min; hold 10uC. The sequencing reactions were purified
with the DyeEx 96 Kit or DyeEx 2.0 Spin Kit (Qiagen) to remove
non-incorporated nucleotides. Analysis of sequences was performed
using MethTools (http://genome.imb-jena.de/methtools/).
Array-based profiling of reference-independent
methylation status (aPRIMES)
aPRIMES was performed according to [45] using 500 ng
genomic DNA that was digested using 10 U MseI (NEB) for 3 h.
The MseI-fragments were then subjected to linker mediated PCR
using primer ddMse11 and primer Lib1 at an initial annealing
temperature of 65uC that was shifted down to 15uC with a ramp of
18uC/min (MWG, Ebersberg, Germany) and ligation using T4-
DNA-Ligase (10 U, Roche) was performed at 15uC overnight.
Half of the resulting ligated MseI fragments were digested with the
restriction enzyme McrBC (NEB) for 8 h and the other half of was
digested with two methylation-sensitive endonucleases, HpaII and
BstUI 3 h each. Proteinase K (Invitrogen) was used for digestion
before amplification using Expand Long Template system
(Boehringer) and Lib1 primer in a MWG thermo cycler; cycling:
72uC: 3 min 20 cycles (94uC: 30 s, 62uC: 30 s, 72uC: 90 s), 72uC:
10 min. The PCR products were recovered by ethanol precipi-
tation and DNA was eluted in 30 mL 0.16 TE, pH 8. In vitro
methylated CpG islands from rice were used as positive controls
for methylation and 10 pg were spiked in DNA samples used for
aPRIMES to control methylation and methylation-sensitive
digestion. Mitochondrial CpG island clones that were present in
the original library were used as controls for unmethylated and
allelically/partially methylated CGIs.
Methyl-CpG-immuno-precipitation (MCIp)
Genomic DNA (2 mg) isolated from CD19 sorted B cells of
either CLL patients or healthy individuals was immuno-precipi-
tated using recombinant MBD2–Fc fusion protein [103]. DNA
was homogenized through a 22G needle and fragmented to a
mean size of 400–500 bp using ultrasonication (2630pulses, 24 s,
10% amplitude, Bioruptor, Diagenode). 30 mg of MBD-Fc protein
was coupled to SIMAG protein-A magnetic beads (Chemicell) 3 h
at 4uC in TBS. After completing MBD-Fc protein binding to the
magnetic beads, precipitation of the sonicated sample DNA was
performed in low salt buffer for 3 h at 4uC. Fractionated elution
from the beads was performed using buffers A–F with increasing
salt concentrations. In order to ensure complete elution of
methylated DNA, elution with buffer F was repeated once. The
collected fractions were desalted using the MinElute Kit (Qiagen)
and eluates were diluted 1:10 and analyzed for control genes
(SNRPN, ZAP70; primer sequences see Table S4) with qPCR.
Samples were subsequently processed for array hybridization.
Chromatin immunoprecipitation (ChIP)
For ChIP 1–56107 viably frozen CD19-sorted B cells from
either CLL patients or healthy individuals were washed once with
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DMEM medium, taken up in 1 ml PBS and formaldehyde cross
link was performed at a final concentration of 1% for 10 min at
RT while rotating. Cross-linked samples were sonicated in 300 ml
SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris/HCl
pH 8.1, 167 mM NaCl, protease inhibitors) 8 times 30 seconds
on/off at high amplitude using a Bioruptor (Diagenode). The
sonicated material was diluted 1:10 with dilution buffer (0.01%
SDS, 1.2 mM EDTA, 16.7 mM Tris/HCl pH 8.1, 1.1%
TritonX100, protease inhibitors), subjected to 1 h preclearing
with 30 ml of salmon sperm saturated protein A/G agarose beads
(Millipore). Precleared chromatin samples were incubated over
night with either 5 mg specific antibody (CTCF, H3K4me2,
macroH2a1.2, Millipore), or 5 mg normal IgGs (Santa Cruz) at
4uC. Antibody bound chromatin was precipitated by adding 50 ml
of salmon sperm saturated protein A/G agarose beads 4 h at 4uC
and unspecifically bound material was removed by washing with
low salt buffer, high salt buffer, LiCl buffer and two times with TE
buffer. Cross link was reversed over night at 65uC and RNaseA
(30 min, 37uC) as well as ProteinaseK digest (2 h, 45uC) was
performed before purification of precipitated DNA using GFXTM
PCR DNA and Gel Band Purification Kit (GE Healthcare).
Precipitation efficiency was analyzed by qPCR for positive and
negative control regions (for primers see Table S4) on antibody
and control IgG precipitated fractions and expressed as percentage
of input DNA using a calibration curve for quantification.
Predicted CTCF binding sites were identified at http://www.
essex.ac.uk/bs/molonc/binfo/ctcfbind.htm.
Array production and hybridization
Microarrays were either produced by spotting PCR-amplified
1 kbp fragments from the promotors of RFP2, DLEU1 and
DLEU2/Alt1 (CpG islands C, D and E) for aPRIMES. For MCIp
arrays were custom designed (eArray, Agilent) to tile promotors
23.8 to +1.8 kbp from the transcriptional start sites of the region
chr13:47702475–49164179 (ITM2B – EBPL) and complete tiling
of the region chr13:49265143–50317955 (C13ORF1 – DLEU7;
GRCh37 hg18). 60 bp oligonucleotides were designed with 30 bp
nonoverlapping spacing. The resulting 9863 oligonucleotides were
combined with 10 bp linker sequence and had an average melting
temperature of 70.43uC. For custom arrays, the 13q14.3
oligonucleotides were complemented with the Agilent normaliza-
tion group (1262) and replicate group (4626) oligonucleotides.
Labeling of ChIP and MCIp samples was performed using the
BioPrime Total Genomic Labeling System (Invitrogen). For
CTCF ChIP samples the precipitate was labeled using Cy5 and
the input was labeled with Cy3. For the MCIp samples only the
elutions from the high salt fraction were labeled, the common
reference (T cell pool) was labeled with Cy3 and the CLL/healthy
donor sample with Cy5. In order to predict labeling efficiency, the
samples were measured at the wavelengths A260, A320, A555,
A650, A750, and the following equations were used to determine
the yield:
Cy3: DNA amount [ mg] (A260–A320)*50*0.04, Dye incorpo-
ration (A555–A650)/0.15*40
Cy5: DNA amount [ mg] (A260–A320)*50*0.04, Dye incorpo-
ration (A650–A750)/0.24*40
The hybridization of the MCIp samples was performed
according to protocol number G4170-90012 for Agilent Micro-
array Analysis of Methlylated DNA Immunoprecipitation version.
1.0. The hybridization of the ChIP samples was performed as
described in the protocol number G4481-90010 for Agilent
Mammalian ChIP-on-chip version 10.1 applying the instructions
given for the 46 format.
Aza-deoxy-cytidine treatment
Cell lines were seeded at a density of 56106 in 4 ml of the
appropriate medium in 6-well plates. After 24 hrs, they were
treated with a final concentration of 1.5 mM 5-Aza-29-deoxycyti-
dine (Sigma-Aldrich) or the respective amount of DMSO solvent
in the control reaction for 6 days with daily medium and drug
replacement.
Chromatin fractionation for sequencing of chromatin-
bound RNA
The chromatin fraction of RNA was prepared from isolated
nuclei after shearing in a Covaris sonicator (Covaris, Inc.). The
sample was then centrifuged and the soluble chromatin was loaded
on a sucrose gradient as described [104]. Fractions containing
DNA fragments . 5000 bp (equivalent to 25 nucleosomes with a
200 bp nucleosome repeat length) were pooled. RNA was phenol/
chloroform-extracted after proteinase K and DNase I treatments
and RNA-sequencing was performed. After rRNA depletion,
RNAs were subjected to metal ion catalyzed cleavage to sizes
between 60–200 nucleotides with the Ambion RNA fragmentation
reagents. Libraries for Solexa sequencing were generated accord-
ing to the standard protocol for mRNA (Illumina) that comprised
first strand cDNA synthesis, second strand cDNA synthesis, end
repair, addition of a single A base and adapter ligation. PCR
products were size excised from low melting agarose gels (200–
400 bp range) and phenol extracted. Sequencing was performed
on the Illumina GAIIx platform at the sequencing core facilities of
the EMBL, DKFZ and BioQuant in Heidelberg, Germany. Initial
RNA sequence analysis was performed with the Bioconductor
(http://www.bioconductor.org) package for the R statistical
programming language to assess the read quality and to produce
a reads coverage file. The integrative genomics viewer (http://
www.broadinstitute.org/igv) was used to visualize the coverage file
and the RefSeq genes (NCBI). Reads were aligned on the
GRCh37/hg19 (2009) assembly version of the human genome
reporting unique hits without mismatches and with and without
trimming of the 39 and 59 ends. Data is available at ArrayExpress
(www.ebi.ac.uk/arrayexpress), Experiment name: lncRNAs at
13q14.3; ArrayExpress accession: E-MTAB-1335 (U2OS) and E-
MTAB-582 (HeLa).
Transfection and knockdown
All cell lines were cultured according to DSMZ (www.dsmz.de)
recommendations. Adherent cell lines were transiently transfected
with indicated constructs using the Nanofectin Kit (PAA). A half
confluent flask of cells was transfected according to manufactures
instructions using 5 mg of DNA for a 25 cm2 flask and 8 mg for a
75 cm2 culture vessel. Suspension cell lines were transfected
according to the Nucleofection protocol of Amaxa (Lonza). For
each cell line 26106 cells were transfected using 5 mg plasmid
DNA (2 mg pmax GFP as transfection control) and 100 ml
Nucleofector solution. The whole procedure was performed
following manufacturer’s instructions and preparing the 12-well
plates with 1.5 ml prewarmed medium. For Nucleofection the
protocol A-023 was used. Gene transcripts were knocked down
using either the Universal probe library system (Roche Diagnos-
tics) and validated by q-RT-PCR to be below 30% of siCONP-
treated cells. siRNAs were also synthesized using the Silencer
siRNA construction kit (Ambion) and modified according to [105],
or validated siRNAs were ordered from Applied biosystems. For
simultaneous transfection of plasmids and miR-mimics (‘‘miRVA-
NAs’’) or miR-inhibitors (both Life Technologies, Darmstadt,
Germany) into HEK293T cells, Lipofectamine2000 (Invitrogen,
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Karslruhe, Germany), Hyperfect (Quiagen) or miRus transit-LT1
(Geneflow) was used. 46105 cells/well were seeded in 24 well
plates and transfected according to the manufacturers instructions
after 24 h using 0.5 mg Plasmid and 10 pmol miR-mimics or miR
inhibitors, respectively. For single transfection of 10 pmol miR-
mimics or miR-inhibitors, the same protocol was used and the cells
harvested after 24 h for Western blot or expression analysis.
Transfection efficiency was tested by transfection of pmaxGFP
(Lonza, Cologne, Germany) or siGlo (Dharmacon, Darmstadt)
and subsequent detection by flow cytometry.
Luciferase assay
RFP2, C13ORF1, and D6/E6 elements in pCpGL. 46105
cells were seeded within a 6-well plate in 2 ml medium and co-
transfected with 250 ng pRL-CMV-Renilla and 750 ng of the
luciferase containing constructs using the appropriate transfection
reagent after 24 h. For the constructs containing/not containing
the D6/E6 element, equimolar amounts of construct were
transfected. After 20–24 h, the cells were stimulated where
indicated with 20 ng/ml TNFa for 10 min. The medium of the
cells was removed and to each well 250 mL of Passive Lysis buffer
(Promega) was added and incubated at RT for 15 min on a shaker.
15 mL of the cell lysates were placed into a 96-well Nunclon White
plate while Luciferase buffer and Renilla buffer were brought to
RT. The plates were measured with the Glomax Luminometer
(Promega) applying the following parameters for both injectors:
injection volume: 75 ml; delay between injection and measure-
ment: 0.4 s; integration time: 5 s. The obtained values for Firefly
Luciferase activity were normalized to Renilla readings to
standardize for transfection efficiency.
miRNA screen. For the NF-kB reporter assay, HEK293FT
cells were transfected in 96-well plates with siRNAs or miRNA-
mimics from Dharmacon (Lafayette, CO, USA) together with
75 ng of the NF-kB reporter 36KBL (kind gift from George
Mosialos, Aristotle University, Thessaloniki, Greece) and 2,5 ng of
pMIR-REPORT b-gal vector (Ambion, Austin, TX, USA). 48 h
after transfection cells were stimulated with TNF-a (20 ng/ml),
and luciferase activity was measured after another 5 h. b-
galactosidase activity was used for normalization, and measured
by beta-glo Luminescent Assay Kit (Promega, Madison, WI,
USA).
Impact of miR-15a, miR-15b, and miR-16 on the
expression of TAB3, IKKa/CHUK, SMRT, and
SMAD7. Parts or complete 39UTRs of TAB3, CHUK, SMRT
and SMAD7 cloned into pMIR-Report Luciferase Plasmid were
transfected into HEK293T cells. To this end, 46105 cells were
seeded in the wells of 24 well plates with 0.45 mg of pMIR-Report,
0.05 mg TK Renilla and 10 pmol of either miR-15a-3p, miR-15a-
5p, miR-15b-5p or miR-16 miR-mimics or miR-inhibitors (Life
Technologies, Darmstadt, Germany), respectively. The cells were
harvested after 24 h and firefly and renilla luciferase activity
measured using the Dual-Luciferase Reporter Assay (Promega)
with injection volumes of 50 ml for LARII and Stop & Glo
solution. Luminescence was measured using the LB940 Multi-
mode Reader Mithras (Berthold Technologies).
Generation of RFP2 antibodies in guinea pigs
Specific antibodies were raised by immunizing guinea pigs with
recombinant RFP2 S154-E264 106His-tagged purified proteins.
Guinea pigs were immunized for the first time at 8 weeks of age
with 100 mg of protein per animal diluted 1:1 with Complete
Freud’s adjuvant (Sigma). Subsequently animals were immunized
monthly with 100 mg of protein per animal diluted 1:1 with
Incomplete Freud’s adjuvant (Sigma). During this process, serum
was taken periodically by heart-punction. After 24 months animals
were bled. Blood was collected in Vacutainer Blood collection
tubes (BD) left at RT for 1 hr and blood cells sedimented by
spinning at 2000 rpm 1 hr at RT. After sedimentation, serum was
collected and aliquoted for storage at 280uC or complemented
with 0.02% sodium azide as preservative and kept at 4uC. The
polyclonal antibodies were tested against purified recombinant
protein in Western blot analysis and against protein over-
expressed in mammalian cells by Western blot analysis and
immunofluorescence.
Statistical methods
Overall survival curves were estimated by the Kaplan-Meier
method. Logrank tests were used for comparing survival distribu-
tions between groups. Wilcoxon rank sum tests were used to test
for differences in expression or methylation distributions between
two groups. For significance of Pearson correlation coefficients, t-
distribution was calculated with t = r/sqrt[(12r‘2)/(N22)]. For
assessment of statistical significance, test results with p-values
p,0.05 were considered to be statistically significant.
Supporting Information
Figure S1 BioCOBRA and MassARRAY analysis allows exact
and robust quantification of DNA-methylation. (Related to
Figure 1, Figure 2, and Figure 3.) (A) Increasing amounts of in
vitro methylated DNA were added to non-methylated DNA and
subsequently analyzed with BioCOBRA for several regions at
13q14.3 (‘‘A’’ to ‘‘E7.2’’) or with MassARRAY for E6. Except for
‘‘B’’, ‘‘miR’’ and ‘‘E6’’, a strict correlation between DNA-
methylation and the quotient of undigested vs total amplicon
was observed. (B) Correlation coefficients (R‘2). (C) DNA-
methylation of the region D6 was quantified in B-cells of four
healthy donors (‘‘H1’’–‘‘H4’’) and seven CLL patients (‘‘P1’’–
‘‘P7’’) using BioCOBRA (black bars). For validation, bisulfite
sequencing of 15–20 clones per sample was performed. Depicted is
the percentage of methylated CpGs of the whole bisulfite-PCR
amplified fragment was calculated (grey bars) as well as the
percentage of methylated CpGs of the BstUI sites that were
addressed in the BioCOBRA assay (white bars). (D) DNA-
methylation of the region E6 was analyzed in B-cells of three
healthy donors (‘‘H1’’–‘‘H3’’) and four CLL patients (‘‘P1’’–‘‘P4’’)
using MassARRAY (black bars) and bisulfite sequencing of 15–20
clones per sample. Shown is the percentage of methylated CpGs of
the whole fragment (grey bars). No BstUI site was located in this
fragment.
(PDF)
Figure S2 Details of the transcriptional start sites of DLEU1 (A),
DLEU2/Alt1 (B) and the homologous region on 3q25.33 (C), (D) a
comparison of 13q14 and 3q25 and details of RB1 (E) and DLEU7
(F). (Related to Figure 1.) (A) D6 is hypomethylated in CLL patients
compared to non-malignant B-cells as measured by aPRIMEs and
BioCOBRA. MCIp for unknown reasons did not faithfully
represent hypomethylation detected by aPRIMES and BioCO-
BRA. (A, B) For details see legend to Figure 1. (C) At the
homologous region in chromosomal band 3q26 that harbors miR-
15b and miR-16-2, TRIM59 and KPNA4, DNA-methylation was
measured by MCIp and transcriptional activity by gene expression
profiling. Only minor differences could be detected between CLL
samples and non-malignant B-cells. Positions refer to genome build
hg18. (D) Regions of 13q14.3 and 3q25.3 have similar coding
potential. Performing pairwise alignment of all protein coding genes
from chr13:50,139,149–51,673,000 and chr3:158,760,141–
160,445,393, a striking protein sequence similarity of a subset of
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protein coding genes (green boxes) was found. TRIM proteins: 57%
similarity, e value: 1e-65; ARL proteins: 62% similarity, e value: 2e-
53; KPNA proteins 92% similarity, e value: 0. Similarly, sequence
alignment of hsa-mir-16-1 and hsa-mir-16-2 showed 68,9% identity
of a 90 bp overlap and alignment of hsa-mir-15a and hsa-mir-15b
showed 56,1% identity of a 98 bp overlap. It can therefore be
speculated that both regions arose from duplication and inversion.
‘‘cen’’ centromeric, ‘‘tel’’ telomeric. (E) DNA-methylation was
measured at an internal CpG island reported to correlate with
imprinting of RB1 by regulating transcription of an alternative
transcript [33]. Differences in DNA-methylation can only be
observed in patients with del13q, possibly caused by gene dosage
effects. (E) The median log 2 fold methylation of 12 tiling array
oligos spanning the CpG island at the transcriptional start site of
DLEU7 (chr 13:50315373–50316150, hg18) were compared
among B cells from healthy donors (n = 7), CLL patients with
retention of both 13q copies (n = 6) and CLL patients with deletion
of one 13q allele (n = 7).
(PDF)
Figure S3 DNA methylation of 13q14.3 sequences does not
correlate with IGHV mutations status and has no prognostic
impact on overall survival, but changes during the clinical course
of the disease. (Related to Figure 2.) (A) Scatterplots of methylation
levels of CpG D6 and CpG E6 in the low risk patient group
(normal karyotype and sole 13q deletion) comparing IGHV
mutated samples with unmutated samples. There are no
statistically significant differences in methylation levels between
IGHV mutated and unmutated groups (D6 mutated: n = 17,
unmutated n = 29; p = 0.1907 and E6, mutated: n = 13, unmu-
tated n = 29; p = 0.2907, Wilcoxon rank sum test). (B, C) Kaplan-
Meier estimates of overall survival of CLL patients (cohort
composition see Table S1) comparing subgroups with different
methylation levels (quartiles) of CpG D6 (A) and CpG E6 (B). In
the analysed patient cohort, no statistically significant differences
could be detected in overall survival distributions between
subgroups (logrank test), suggesting that DNA-demethylation at
13q14.3 is common to all CLL. (D) Analysis of changes in DNA-
methylation in D6 over time in CLL PBMC samples. Left panel:
Exemplary result for 6/10 patients where changes in methylation
in the PBMC sample (red line) correlated with the changes in the
content of CLL cells in the sample (blue line) as expected. Content
of CLL cells was identifed from the percentage of CD5/CD19
double positive cells of all peripheral blood lymphocytes. Other
panels: Four patients showed disproportional loss/gain of DNA-
methylation, suggesting correlation of DNA-methylation with the
clinical course of the disease. Right panel: In one patient, DNA-
demethylation at 13q14.3 was directly associated with the clinical
course of the disease. ‘‘P’’ = patient, ‘‘T’’ = therapy. ‘‘*’’ = progres-
sive disease.
(PDF)
Figure S4 In vitro manipulation of DNA-methylation of D6 and
E6 regions confirms functional relevance for gene expression.
(Related to Figure 3.) (A, B) Haematopoetic and non-haemato-
poetic cell lines where tested for basal DNA methylation levels in
D6/E6 using COBRA (A, n = 16) and MassARRAY analysis (B,
n = 17) respectively. COBRA was controlled using in vitro
methylated (‘‘m’’) and in vitro amplified non-methylated (‘‘um’’)
Granta-519 genomic DNA as control and a plasmid containing
several BstuI restriction sites. Jurkat, Raji and HEK cells carried
methylation at both the D6 and E6 region. Only Jurkat cells
showed full methylation at the D6 region and 70% methylation at
the E6 region similar to B cells from healthy donors. Thus, only
Jurkat cells were suited to study the impact of D6 and E6
methylation on the expression levels of 13q14.3 genes after
treatment with 5-aza-29-deoxycytidine. (C–F) DNA-demethylation
of Jurkat cells in-vitro leads to an upregulation of 13q14.3 genes,
but not of miRNA genes. Regions D6 (C) and E6 (D) that are
differentially methylated in CLL patients and a CpG island
reported to modulate RB1 expression (E) become demethylated in
Jurkat cells upon 5-aza-29-deoxycytidine treatment. (F) This
demethylation leads to an increased expression of genes localized
in the critical region with the exception of the miRNA genes that
are post-transcriptionally regulated (Allegra, manuscript submit-
ted). Gene expression was measured as in Figure 3. (G) The
promoter of DLEU2/Alt1, the flanking CpG island E and the
region E6 were cloned into the pCpGL luciferase vector. (H–J)
Constructs depicted in G were either methylated in-vitro using SssI
methylase (‘‘m’’) or left unmethylated (‘‘um’’) and subsequently
transfected into HeLa, Granta519 and Mec1 cells. Promoter
activity in HeLa was very low, suggesting that essential functional
elements are missing in non-hematopoietic cells. In general,
luciferase activity was lower than for the D6 constructs (Figure 4F
and 4G), possibly because of the larger size of the constructs (7.9
and 7.4 kbp (E6) vs 5.9 and 5.2 kbp (D6)). Blue boxes mark
constructs cloned in the physiological orientation. (K) Schematic
representation of regions analyzed for CTCF enrichment by
ChIP-qPCR. Red lines represent predicted CTCF binding sites
(http://bsproteomics.essex.ac.uk:8080/bioinformatics/ctcfbind.
htm). Green boxes represent amplicons of ChIP qPCR and blue
boxes represent D6 and E6 elements, respectively. Genomic
locations are depicted on top of each panel.
(PDF)
Figure S5 RNA–seq of chromatin-bound RNA shows no
enhanced binding of DLEU1 and DLEU2 to chromatin. (Related
to Figure 3). (A) In HeLa and U2OS cells, DLEU1 and DLEU2 do
not show higher enrichment in the chromatin-bound RNA
fraction when compared to the neighboring protein-coding genes
and to total RNA. This suggests that they do not act via binding to
chromatin. Localization of DLEU1 and DLEU2 is represented by
the red box (top panel). Lines denote genes, blue boxes denote
exons, arrows give direction of transcription. Blue bars represent
numbers of reads, normalized to the highest peak whose number
of reads is given at the left. (B) RNA-seq of chromatin-bound
lncRNA genes used as controls. LncRNA reported to bind to
chromatin show either specific enrichment in the chromatin-
bound fraction (XIST and Tsix in mouse embryonic stem cells) or
binding of specific sequences to chromatin (MALAT1 and TERC in
HeLa and U2OS cells).
(PDF)
Figure S6 13q14.3 candidate genes are involved in NF-kB
signaling. (Related to Figure 4.) (A) Knockdown of 13q14.3
candidate tumor suppressor genes results in reduced activation of
NF-kB by TNFa. KPNA3, KCNRG, RFP2 and C13ORF1 were
knocked down in HEK293T cells and activity of NF-kB was
measured after 24 hrs with a second reporter construct containing
5 synthetic NF-kB recognition sites. As negative control, a siRNA
without physiological target was used (siCONP). Error bars signify
SEM of 3 experiments. (B) RFP2 induces NF-kB activity in
HEK293 cells. HEK293 cells were transiently transfected with
CMV RFP2 expression plasmids (‘‘+’’) or empty vector (‘‘2’’) and
NF-kB activity was measured after 4, 7, 10, 12 and 24 hrs (bottom
panel). The top panel shows a representative Western blot of two
experiments, error bars in bottom panel represent standard
deviation of triplicate measurements. (C) Induction of NF-kB is
not due to ectopic overexpression of protein. EVSAT, HEK293T
and HeLa cells were transfected with increasing amounts of
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expression plasmids containing RFP2 or GFP. GFP-Fluorescence
visualized by microscopy validated functionality and efficiency of
transfection of the GFP plasmid (not shown). NF-kB activity was
measured with luciferase reporter assay (for detailed description
see Figure 6). Already 100 ng of RFP2 expression plasmid induced
NF-kB activity, while no or little activity was induced with 5 mg of
GFP expression plasmid. (D) Transfection of C13ORF1 expression
plasmids into HEK293 and HEK293T cells alone or in
combination with RFP2 or RFP2mut expression plasmids does
not result in additional activation of NF-kB activity as measured by
luciferase reporter assay. Error bars represent standard deviation
of 3 independent experiments. (E) Knockdown of ATP2A2 and
SQSTM1 does not modulate activation of NF-kB after transfection
of RFP2, but knockdown of VCP substantially increases activation
of NF-kB by RFP2. ATP2A2/SERCA2, SQSTM1 and VCP were
knocked down and plasmids for overexpression of RFP2 and
luciferase reporters detecting NF-kB activity were transfected after
24 hrs into HEK-293. While no or only a minor change could be
observed after knockdown of ATP2A2/SERCA2 and SQSTM1,
respectively, knockdown of VCP led to a substantial increase in the
activation of NF-kB after cotransfection of RFP2. Error bars depict
variation of two independent experiments.
(PDF)
Table S1 Characteristics of CLL patient cohort (n = 143).
(PDF)
Table S2 Characteristics of healthy donor cohort (n = 43).
(PDF)
Table S3 Transcription factors whose binding motifs are present
in the D6 and/or E6 element were predicted using PATCH
pattern search for transcription factor binding sites selecting a
lower score boundary of 87.5.
(PDF)
Table S4 Primer sequences.
(PDF)
Table S5 miRNA families tested for induction of NF-kB, ranked
according to their induction of NF-kB. (Related to Figure 4.)
(PDF)
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